Featured 13F manager
Gilead Sciences, Inc.
Foster City, CA 4 processed 13Fs on this site · 2025 Q3–2026 Q2
- $1.6B
- 5 Positions
- 2026 Q2
- −22.1% QoQ
- Top 5 100.0%
Gilead Sciences, Inc. files a Form 13F. The latest book is 2026 Q2 at $1.6B, down 22.1% QoQ, led by Arcus Biosciences, Lakefront Biotherapeutics, and Assembly Biosciences.
Portfolio
top 5 100.0% · top 10 100.0%
- RCUS - Arcus Biosciences 58.8%
- LKFT - Lakefront Biotherapeutics 30.3%
- ASMB - Assembly Biosciences 8.3%
- Kyverna Therapeutics 2.2%
- Xilio Therapeutics 0.4%
AUM over time
Latest book
| RCUS - Arcus Biosciences | 58.76% | Hold | 31,424,760 | $30.83 | $969M | — | — |
| LKFT - Lakefront Biotherapeutics | 30.34% | Hold | 16,707,477 | $29.94 | $500M | — | — |
| ASMB - Assembly Biosciences | 8.30% | Add +10.5% | 4,977,089 | $27.48 | $137M | +471,698 | +$12M |
| Kyverna Therapeutics | 2.23% | Hold | 4,126,119 | $8.91 | $37M | — | — |
| Xilio Therapeutics | 0.38% | Hold | 650,389 | $9.58 | $6M | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2026 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ACLXGBX - Arcellx | 36.44% | Exit | 0 | $114.82 | $772M | −6,720,803 | −$772M |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 5 | $1.6B | −22.1% | 13F-HR | 8/3/2026 | 000112329226001034 |
| 2026 Q1 | 6 | $2.1B | +9.4% | 13F-HR | 5/8/2026 | 000112329226000642 |
| 2025 Q4 | 6 | $1.9B | +8.1% | 13F-HR | 2/12/2026 | 000112329226000164 |
| 2025 Q3 | 9 | $1.8B | — | 13F-HR | 11/13/2025 | 000112329225000642 |
About
Gilead Sciences, Inc.
4 processed 13Fs on this site · 2025 Q3–2026 Q2